Quarterly report · Q2
4576.TEDINET S100OU2V
Period2022-01-01 → 2022-06-30
Filed2022-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥210m | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥414m | 2021-01-01 → 2021-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥202m | 2021-01-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥132m | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥91m | 2021-01-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥118m | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥160m | 2021-01-01 → 2021-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥82m | 2021-01-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥118m | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥82m | 2021-01-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥110m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥149m | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥83m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥119m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥83m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥2.3bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥2.5bn | at 2021-12-31 | Cons. | Assets |
| Total assets | ¥2.6bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥358m | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥428m | at 2021-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.9bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2021-12-31 | Cons. | Net assets |
| Net assets / equity | ¥2.1bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.9bn | at 2021-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥130m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥176m | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥75m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥111m | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥100m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥76m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥104m | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥43m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-3.76 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.01 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.08 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.83 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.42 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 83.5% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.4% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.0% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 387
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of investment securities inv cf | Prior1YTDDuration | -100320000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | － | JPY |
| Decrease increase in guarantee deposits inv cf | Prior1YTDDuration | 897000 | JPY |
| Decrease increase in guarantee deposits inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -100007000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -4077000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -60000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -60000000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | 16620000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | － | JPY |
| Purchase of treasury share acquisition rights fin cf | Prior1YTDDuration | － | JPY |
| Purchase of treasury share acquisition rights fin cf | CurrentYTDDuration | -2692000 | JPY |
| Commission expenses paid fin cf | Prior1YTDDuration | － | JPY |
| Commission expenses paid fin cf | CurrentYTDDuration | -13200000 | JPY |
| Other net fin cf | Prior1YTDDuration | － | JPY |
| Other net fin cf | CurrentYTDDuration | -499000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -43379000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -76391000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 10177000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 26462000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -207890000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -184428000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2308210000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1933743000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 2100319000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1749315000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 57879000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 50873000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)東海財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-09 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第25期第２四半期（自 2022年４月１日 至 2022年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社デ・ウエスタン・セラピテクス研究所 | |
| Company name in english cover page | FilingDateInstant | D.Western Therapeutics Institute, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 日 高 有 一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)名古屋市中区錦一丁目18番11号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 052－218－8785 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役総務管理部長 川 上 哲 也 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)名古屋市中区錦一丁目18番11号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 052－218－8785 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役総務管理部長 川 上 哲 也 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E22024 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45760 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社デ・ウエスタン・セラピテクス研究所 | |
| Filer name in english | FilingDateInstant | D.Western Therapeutics Institute, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |